<code id='97B555CC2C'></code><style id='97B555CC2C'></style>
    • <acronym id='97B555CC2C'></acronym>
      <center id='97B555CC2C'><center id='97B555CC2C'><tfoot id='97B555CC2C'></tfoot></center><abbr id='97B555CC2C'><dir id='97B555CC2C'><tfoot id='97B555CC2C'></tfoot><noframes id='97B555CC2C'>

    • <optgroup id='97B555CC2C'><strike id='97B555CC2C'><sup id='97B555CC2C'></sup></strike><code id='97B555CC2C'></code></optgroup>
        1. <b id='97B555CC2C'><label id='97B555CC2C'><select id='97B555CC2C'><dt id='97B555CC2C'><span id='97B555CC2C'></span></dt></select></label></b><u id='97B555CC2C'></u>
          <i id='97B555CC2C'><strike id='97B555CC2C'><tt id='97B555CC2C'><pre id='97B555CC2C'></pre></tt></strike></i>

          Home / knowledge / comprehensive

          comprehensive


          comprehensive

          author:knowledge    Page View:76
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In